Aurobindo and Huons refocus their biologicals/biosimilars portfolios

Home/Pharma News | Posted 23/10/2020 post-comment0 Post your comment

India-based generics maker Aurobindo Pharma (Aurobindo) has announced a renewed product focus and plans for the biosimilars of its subsidiary company. In addition, Korea-based Huons will collaborate with Singapore-based Prestige BioPharma’s (Prestige) to enter the biosimilars market.


New biologicals and biosimilars for Aurobindo
In August 2020, Aurobindo announced that it is developing five biological products, alongside a portfolio of 14 biosimilars [1]. It will be filing the first two products for European approval towards the end of 2020 or in early 2021, which could allow for launch in 2022. In addition, the company is developing an ophthalmic product, for which it expects to start a phase III clinical trial early 2021. The company hopes to file for approval of this in both the European Union and the US.

In the development of new products, Aurobindo has focussed on biological products with patents expiring in 2024. In their annual report, they stated that at least two products from this portfolio will progress to animal toxicity studies next year and subsequently move on to clinical trials.

This announcement follows Aurobindo’s transferral of its entire biosimilars business to its subsidiary company CuraTeQ Biologics [2]. It is hoped that in moving all of its biologicals to a subsidiary, owned 100% by Aurobindo, will lead the company to have better focus and review.

Huons invests in biosimilars
Later in August 2020, Huons announced its agreement with Prestige Bio Pharmaceutical, the Korean branch of Singapore-based Prestige BioPharma. Here, Huons will have exclusive Korean sales rights for HD204, an Avastin biosimilar, and PBP1502, a Humira biosimilar. These will combine with the exclusive sales rights that the company already has for Prestige’s HD201, a Herceptin biosimilar. Huons will also invest in Prestige Bio Pharmaceutical as it believes that the introduction of biosimilars to their business is essential at this time.

Related articles
Huons enters biosimilar market while private equity firm PAG invests in Hisun BioRay

Aurobindo and Lannett expand their generics portfolios

Biosimilars approved in the US

1. GaBI Online - Generics and Biosimilars Initiative. Aurobindo Pharma receives FDA approval for three generics []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 23]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Aurobindo/Sandoz deal falls through, biosimilars business transferred to subsidiary []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 23]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010